John Carter
Physician Assistant · Staunton, VANPI 1821583329
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 84.0% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $36,680, more than ten times the $2,867 reported in 2021. Among physician assistant clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,118 payments — averaging $80.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$76K
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $6K from 25 others
What the payments were for
- Consulting fees$17,06319%
- Speaking & faculty fees$49,69455%
- Travel & lodging$6,3367%
- Food & beverage$16,80019%
- Education$4931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 143 | $75,937 |
| AbbVie(2 entities) | 165 | $2,657 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 229 | $2,196 |
| Lundbeck LLC | 104 | $1,355 |
| Otsuka America Pharmaceutical, Inc. | 113 | $1,341 |
| Teva Pharmaceuticals USA, Inc. | 64 | $1,327 |
| Johnson & Johnson | 46 | $997 |
| Alkermes, Inc. | 56 | $921 |
| Vanda Pharmaceuticals Inc. | 37 | $737 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $478 |
| E.r. Squibb & Sons, L.L.C. | 16 | $384 |
| Axsome Therapeutics, Inc. | 22 | $324 |
| Corium, LLC | 15 | $315 |
| Supernus Pharmaceuticals, Inc. | 13 | $296 |
| Noven Therapeutics, LLC | 10 | $146 |
| Eisai Inc. | 5 | $146 |
| Avanir Pharmaceuticals, Inc. | 5 | $124 |
| Sunovion Pharmaceuticals Inc. | 13 | $124 |
| Ironshore Pharmaceuticals Inc. | 4 | $90 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Collegium Pharmaceutical, Inc. | 4 | $62 |
| Novo Nordisk | 3 | $59 |
| Almatica Pharma LLC | 3 | $57 |
| Neuronetics, Inc. | 2 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $49 |
| Bausch Health US, LLC | 2 | $42 |
| Livanova USA, Inc. | 2 | $37 |
| Indivior Inc. | 2 | $30 |
| Bioxcel Therapeutics, Inc. | 1 | $19 |
| Noven Pharmaceuticals, Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,386 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 52 | $106,433 |
| Invega SustennaPaliperidone Palmitate | 22 | $71,749 |
| VraylarCariprazine Hcl | 16 | $26,464 |
| Abilify MaintenaAripiprazole | 12 | $22,886 |
| TrintellixVortioxetine Hydrobromide | 23 | $20,405 |
| Aripiprazole | 233 | $17,540 |
| Clozapine | 162 | $11,786 |
| Divalproex Sodium ErDivalproex Sodium | 76 | $8,035 |
| Duloxetine Hcl | 235 | $6,830 |
| Quetiapine Fumarate | 253 | $6,058 |
| Divalproex Sodium | 74 | $5,515 |
| Risperidone | 384 | $5,078 |
| Paliperidone ErPaliperidone | 26 | $3,343 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 12 | $3,245 |
| Mirtazapine | 79 | $3,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,341 | $129,31964 claims |
| Johnson & JohnsonInvega Sustenna | $997 | $71,74922 claims |
| AbbVieVraylar | $2,657 | $26,46416 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $478 | $20,40523 claims |
| Almatica Pharma LLCSertraline Hcl | $57 | $1,889200 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Staunton
- Stephanie BrutonStaunton$15K
- Lauren FacklerStaunton$12K
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Robert HigginsonRichmond$66K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.